5/26 Taiwan Life Sciences Weekly Newsletter
2025-05-26 |
| Taiwan Life Sciences Weekly |
| Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTnm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting Press release 23 May, 2025 GNTbm (TW: 7427) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which is held in Chicago, USA, from May 30 to Jun 04, 2025. More... |
| Handa Pharmaceutical's US subsidiary secures FDA approval for generic smoking cessation aid HND-032 22 May, 2025 Handa Pharmaceuticals (TW: 6620) announced on behalf of its US subsidiary, Handa Pharmaceuticals, LLC, that its smoking cessation aid HND-032 has passed the US FDA's review for a generic drug application and received final approval. More... (in Chinese) |
| Acer Medical enters Central American smart healthcare market with diabetic retinopathy early screening diagnostics 22 May, 2025 Acer Medical (TW: 6857) announced that the company's ARC-1000 Non-Mydriatic Automated Fundus Camera and its VeriSee DR AI-Assisted Diagnostic Software for Diabetic Retinopathy have been deployed in Belize, a diplomatic ally of Taiwan in Central America. These tools will support local public healthcare institutions and the Belize Council for the Visually Impaired in enhancing early screening capabilities for diabetic retinopathy. Acer stated that this initiative is part of the Belize Metabolic Chronic Disease Prevention and Control Project, jointly promoted by the Taiwan International Cooperation and Development Fund (TaiwanICDF), Far Eastern Memorial Hospital, and Belize’s Ministry of Health & Wellness. More... (in Chinese) |
| Oneness Biotech's Fespixon demonstrates cost-saving pharmacoeconomic advantages in Singapore 22 May, 2025 Oneness Biotech (TW: 4743) announced that its new drug Fespixon (development code ON101) was the subject of a pharmacoeconomic analysis indicating clear cost-saving advantages within Singapore's healthcare setting. The findings have been accepted for publication by the internationally renowned SCI journal Diabetes, Obesity and Metabolism, supporting Fespixon's clinical efficacy and pharmacoeconomic value, and also provided evidence for its potential inclusion as a standard treatment under Singapore’s national health insurance system. By modulating wound macrophages, Fespixon improves the local immune environment of diabetic foot ulcers (DFU). The drug has efficacy in accelerating healing validated through international multicenter Phase III clinical trials. More... (in Chinese) |
| MIRDC Establishes CDMO Innovation Center in Boston to Advance into Innovative Healthcare 22 May, 2025 On May 16, The Metal Industries Research & Development Centre (MIRDC) officially established its CDMO Center in Boston. Supported by Taiwan's Department of Industrial Technology (DoIT), Ministry of Economic Affairs, the initiative aims to strengthen future Taiwan-U.S. collaborations in medical technology innovation and pave the way for Taiwanese biomedical companies to enter the US market. More... |
| MOFA organizes smart medicine forum in Geneva 22 May, 2025 The Ministry of Foreign Affairs staged a seminar on smart medical devices May 18 in Geneva, highlighting the government's commitment to advancing global health care. Representatives from Acer Medical, based in New Taipei City, and Quanta Computer Inc., headquartered in the northern city of Taoyuan, briefed the audience on smart medical tools, the MOFA said. The event drew over 100 attendees, including World Health Assembly delegates from various countries, international medical teams and local professionals. More... |
| Taiwan's Biotech Bet: DCB's Role in Advancing Exosome Therapy 22 May, 2025 In the bustling hub of Taiwan's Nangang National Biotechnology Park, the Development Center for Biotechnology (DCB) stands as a linchpin in the nation's biotech ambitions. For 40 years, DCB has evolved alongside the industry, bridging academia and enterprise to propel Taiwan onto the global stage. At the forefront of this mission is Dr. Tsai-Kun Li, DCB's Vice President, whose insights into the burgeoning field of exosome and extracellular vesicle (EV) therapies illuminate both Taiwan's potential and its challenges. In an engaging discussion, Dr. Li outlined how DCB is fostering innovation, navigating regulatory hurdles, and positioning Taiwan as a key player in this transformative biotech frontier. More... |
| OBI Pharma's subsidiary Innova aims to list on Taiwan's Emerging Stock Board by year-end 21 May, 2025 OBI Pharma (TW: 4174) subsidiary Innova Biotech has announced plans to register on the emerging stock board by the end of the year. Innova stated that its core product -- the 760 kDa Taiwan-derived botulinum toxin in Phase II clinical trials -- is expected to have its data unblinded by the end of August, followed by the initiation of licensing discussions. Additionally, Innova plans to enter the US market, aiming to submit an Investigational New Drug (IND) application to the US FDA by the end of this year. More... (in Chinese) |
| Germany–Taiwan Healthcare Partnership: Five Innovative German Companies Visit Taiwan for Collaboration 20 May, 2025 Taiwan's healthcare system is widely recognized as one of the most advanced and accessible in the world. Even during the pandemic, it demonstrated remarkable resilience, supported by a comprehensive and affordable National Health Insurance (NHI) program. However, with a rapidly aging population and a growing shortage of healthcare professionals, the system is now under increasing pressure. In light of these challenges and to further deepen bilateral cooperation in the healthcare sector, the German Trade Office Taipei's service unit, DEinternational Taiwan Ltd., hosted the Taiwanese-German Conference on Healthcare Applications today. The conference is part of a delegation trip of German companies to Taiwan, which is funded by the Federal Ministry of Economic Affairs and Energy under the market entry program, and serves as a key component of a German business delegation's visit to Taiwan. More... |
| Mycenax launches commercial-scale production of biologic drug for Japan client 19 May, 2025 Mycenax (TW: 4726) announced that following approval from Japan's PMDA (Pharmaceuticals and Medical Devices Agency) after a facility inspection in February this year, the company recently received notice that the product has successfully obtained PMDA approval for manufacturing site transfer. Mycenax stated that the company has now officially become a commercial-scale manufacturer for an approved biologic drug. In addition, Mycenax has signed a long-term supply agreement with its Japanese client, laying a solid foundation for future revenue growth. More... (in Chinese) |
| Future PharmaTech and Panion & BF Biotech complete new drug licensing deal 18 May, 2025 Taiwan's Future PharmaTech announced that it has completed a commercial licensing agreement for its first new drug, FPT01, developed for treating sexual dysfunction. The company has signed a collaboration contract with Panion & BF Biotech (TW: 1760). According to Future PharmaTech, the agreement grants Panion & BF Biotech exclusive sales rights for FPT01 in Taiwan, along with the first right of negotiation for the markets in China, Hong Kong, and Macau. The licensing deal includes an upfront payment, milestone payments, and sales royalties. More... (in Chinese) |
| Foxconn Taps NVIDIA to Accelerate Physical and Digital Robotics for Global Healthcare Industry Press release / Promotional article 18 May, 2025 The global healthcare system is expected to face a shortage of 4.5 million nurses by 2030 -- and one of the main causes is high burnout. Manufacturing giant Foxconn is helping ease the burden with NVIDIA-accelerated solutions like Nurabot, a collaborative nursing robot that offloads time-consuming, fatiguing tasks such as transporting medication and samples across the hospital. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |